Dr Reddy’s Laboratories Ltd has announced the first-to-market launch of naproxen and esomeprazole magnesium delayed-release tablets, a therapeutic equivalent generic version of Vimovo, approved by the US Food and Drug Administration (FDA).
“This launch is a testament to our core strengths in the areas of research and development and intellectual property,” Marc Kikuchi, chief executive officer, North America Generics, Dr Reddy’s, said in a release.
Also read: USFDA approves Veyonda + doxorubicin: Noxopharm
“We are excited to be a part of forming the first generic market for Vimovo tablets and to provide an affordable treatment alternative for patients, ”the company added.
The Vimovo brand had US sales of approximately US$ 414 million for the 12 months ended December 2019, according to IQVIA Health.
